This phase III study, led by Drs. Patrick Forde and Anna Nowak, is evaluating durvalumab immunotherapy during and after standard chemotherapy versus chemotherapy alone
Already among the most influential thought leaders in cardio-oncology, Dr. Ky is the first in this field to receive the Group’s highest research distinction
This phase III trial is testing the antibody durvalumab added to standard chemoradiation followed by durvalumab for one year, compared to standard chemoradiation followed by one year of the antibody